Urologic An issue of Salvage therapies for Non-Muscle Invasive Bladder Cancer, 1st Edition
Author :
Badrinath Konety
Date of Publication: 12/2019
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the fol ...view more
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy. Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy. Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.
Bring it with you - The Bookshelf app allows you to access books on your laptop, tablet or mobile, so your ebooks go where ever you are - online or offline.
Take notes - Highlight, bookmark and take notes and highlights automatically stay in sync no matter where you make them.
Listen to eBooks - When you need to go screenless, the Text-to-speech tool will read your book aloud.
Powerful search - The searching capabilities allow you to search keywords through all your eBooks, the entire Bookshelf Library and well as on Wikipedia.
Ecological - Manage your environmental impact with paperless books.
How to read your VitalSource eBooks
Purchase your VitalSource eBook on the Elsevier Health site
https://www.mea.elsevierhealth.com/urologic-an-issue-of-salvage-therapies-for-non-muscle-invasive-bladder-cancer-9780323722568.html95499Urologic An issue of Salvage therapies for Non-Muscle Invasive Bladder Cancerhttps://www.mea.elsevierhealth.com/media/catalog/product/9/7/9780323722568_1.jpg98.09108.99USDInStock/Medicine and Surgery/Urology/Medicine and Surgery/Surgery/Urology/Books/Clinics Review Articles9933993452550395612838137337499185145120Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy. Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer. Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics: BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy. Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.USD00add-to-cart97803237225682019ProfessionalBy Badrinath Konety20201BookOtherElsevier2405 Dec 2019PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSBy <STRONG>Badrinath Konety</STRONG>ClinicsThe Clinics: SurgeryNoNoNoNoPlease SelectPlease SelectPlease Select